Theravance, UBC, Uptake Medical and VantagePoint Management; has given lectures for the American Thoracic Society, AstraZeneca, Boehringer Ingelheim, California Allergy Society, Creative Educational Concept, France Foundation, Information TV, Network for Continuing Ed, Novartis, Pfizer and SOMA; and has received industry-sponsored grants from AstraZeneca, Biomarc, Centocor, Mpex, Nabi, Novartis and Otsuka. DAL has received grant support, consultancy fees and honoraria from GlaxoSmithKline, consultancy fees from Talecris Biotherapeutics, Genzyme and Amicus Therapeutics and honoraria from LKB. JV has received honoraria for consulting and presenting for pharmaceutical companies with an interest in COPD, and is an investigator on the ECLIPSE study and the International COPD Genetics Network, both sponsored by GlaxoSmithKline.

Ethics approval This study was conducted with the approval of the Partners IRB.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

1. **Rachet B**, Siemiatycki J, Abrahamowicz M, *et al*. A flexible modeling approach to estimating the component effects of smoking behavior on lung cancer. *J Clin Epidemiol* 2004;**57**:1076–85.
2. **Hoffmann K**, Bergmann MM. Modeling smoking history: a comparison of different approaches. *Am J Epidemiol* 2003;**158**:393–4.
3. **Dockery DW**, Speizer FE, Ferris BG Jr, *et al*. Cumulative and reversible effects of lifetime smoking on simple tests of lung function in adults. *Am Rev Respir Dis* 1988;**137**:286–92.
4. **Burrows B**, Knudson RJ, Cline MG, *et al*. Quantitative relationships between cigarette smoking and ventilatory function. *Am Rev Respir Dis* 1977;**115**:195–205.
5. **Xu X**, Dockery DW, Ware JH, *et al*. Effects of cigarette smoking on rate of loss of pulmonary function in adults: a longitudinal assessment. *Am Rev Respir Dis* 1992;**146**:1345–8.
6. **Stavem K**, Aaser E, Sandvik L, *et al*. Lung function, smoking and mortality in a 26-year follow-up of healthy middle-aged males. *Eur Respir J* 2005;**25**:618–25.
7. **DeMeo DL**, Sandhaus RA, Barker AF, *et al*. Determinants of airflow obstruction in severe alpha-1-antitrypsin deficiency. *Thorax* 2007;**62**:806–13.
8. **Patel BD**, Coxson HO, Pillai SG, *et al*. Airway wall thickening and emphysema show independent familial aggregation in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2008;**178**:500–5.
9. **Silverman EK**, Chapman HA, Drazen JM, *et al*. Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease. Risk to relatives for airflow obstruction and chronic bronchitis. *Am J Respir Crit Care Med* 1998;**157**:1770–8.
10. **Pillai SG**, Ge D, Zhu G, *et al*. A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. *PLoS Genetics* 2009;**5**:e1000421.
11. **American Thoracic Society**. Standardization of spirometry, 1994 update. *Am J Respir Crit Care Med* 1995;**152**:1107–36.
12. **Fletcher C**, Peto R. The natural history of chronic airflow obstruction. *BMJ* 1977;**1**:1645–8.
13. **Kerstjens HA**, Rijcken B, Schouten JP, *et al*. Decline of FEV₁ by age and smoking status: facts, figures, and fallacies. *Thorax* 1997;**52**:820–7.
14. **Sorheim IC**, Bakke P, Gulsvik A, *et al*. Alpha-1 antitrypsin PI MZ heterozygosity is associated with airflow obstruction in two large cohorts. *Chest* 2010;**138**:1125–32.
15. **Hersh CP**, Dahl M, Ly NP, *et al*. Chronic obstructive pulmonary disease in alpha-1-antitrypsin PI MZ heterozygotes: a meta-analysis. *Thorax* 2004;**59**:843–9.
16. **Hatsukami DK**, Benowitz NL, Rennard SI, *et al*. Biomarkers to assess the utility of potential reduced exposure tobacco products. *Nicotine Tob Res* 2006;**8**:600–22.
17. **Borgerding M**, Klus H. Analysis of complex mixtures—cigarette smoke. *Exp Toxicol Pathol* 2005;**57**(Suppl 1):43–73.
18. **O'Connor RJ**, Kozlowski LT, Hammond D, *et al*. Digital image analysis of cigarette filter staining to estimate smoke exposure. *Nicotine Tob Res* 2007;**9**:865–71.
19. **Mooney M**, Green C, Hatsukami D. Nicotine self-administration: cigarette versus nicotine gum diurnal topography. *Hum Psychopharmacol* 2006;**21**:539–48.

Journal club

Early administration of neuromuscular blockers may increase survival in ARDS

Acute respiratory distress syndrome (ARDS) has a very high mortality and few interventions exist that have a direct effect on the mortality and morbidity of this condition. Although previously used, neuromuscular blockade has not been popular in recent years with long-term muscular weakness often cited as a reason for non-use.

This placebo controlled trial recruited 340 patients with rapid onset of severe ARDS, all of whom were managed on a protective lung ventilation strategy. Half received a cisatracurium infusion for 48 h and the other half placebo. The primary endpoint was 90-day mortality rate. Mortality was significantly decreased in the cisatracurium group as opposed to the placebo group. This group also had fewer pneumothoraces and more days free of multi-organ failure. Patients with severe hypoxaemia seemed to benefit the most. This study found no significant difference in the incidence of ICU-acquired paresis between the groups at ICU discharge.

Further studies will be required to assess whether duration of neuromuscular blockade affects mortality and whether this benefit can be applied to other neuromuscular blocking agents, and to ascertain the mechanism behind the benefit of paralysis.

► **Papazian L**, Forel JM, Gacouin A, *et al*; for the ACURASYS Study Investigators. Neuromuscular blockers in early acute respiratory distress syndrome. *N Engl J Med* 2010;**363**:1107–16.

J S Biswas

Correspondence to JS Biswas, Specialist Registrar, University College Hospital, 235 Euston Road, London NW1 2BU, UK; jason.biswas@nhs.net

Published Online First 15 December 2010

Thorax 2011;**66**:909. doi:10.1136/thx.2010.156075